GotoPER - Physicians' Education Resource

Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-line Care of Patients With mRCC

08/08/2022

Register Now

August 8th, 6:30 pm - 8:30 pm EDT

Fee: Free

Overview

Seventy-nine thousand patients will be diagnosed with renal cell carcinoma (RCC) this year, and approximately 13,900 will die from the disease in the US alone. Early detection is associated with a better 5-year survival rate (SR); however, the 5-year SR drops drastically from localized disease (92.6%) to distant disease (11.7%). RCC management is undergoing rapid changes, and the numerous therapies available challenge health care professionals to keep up-to-date with an ever-expanding armamentarium.

During this live Show Me Your Care Plan! webcast, a panel of distinguished specialists will engage in spirted discussions about the latest data on current and emerging therapeutic strategies for the management of metastatic RCC and explore practical approaches to patient counseling and evidence-based strategies for the early detection and management of treatment-related adverse events. Case studies and lively panel discussions will place new developments into clinical context to help participants optimize care for patients with RCC.

Benefits of Attending

  • Understand the latest treatment strategies available for patients with mRCC
  • Learn effective approaches to educate patients about the disease, its treatment, and treatment-related adverse effects (AEs)
  • Review evidence-based methods for early identification and management of treatment-related AEs
  • Explore ways to facilitate patient engagement in clinical trials

Target Audience

This educational program is directed toward nurses, pharmacists, and other health care professionals interested in the treatment of renal cell carcinoma.


Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess practice-changing evidence on current and emerging frontline treatment options for patients with renal cell carcinoma (RCC)
  • Incorporate best practices for monitoring and mitigating adverse events associated with targeted therapies and immunotherapies used in the frontline treatment of patients with advanced/metastatic RCC
  • Apply personalized strategies to counsel patients concerning their frontline treatment plan, including potential treatment-related toxicities and the proactive plan for their identification and management
  • Evaluate emerging therapies in clinical trials that may provide additional frontline treatment options for patients with advanced/metastatic RCC

Accreditation/Credit Designation

Physicians’ Education Resource, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hour (0.20 CEU) under the ACPE universal activity number 0661-0000-22-003-H01-P. The activity is available for CE credit through August 8, 2023.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Pfizer, Inc.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

See all upcoming events

Related Content